Insider buying last 90 days
No open-market insider purchases were filed for IDYA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IDYA insider filing, plotted on the chart in Gekko.Open IDYA in Gekko
NASDAQ: IDYA
IDEAYA Biosciences (IDYA) Stock Analysis & Forecast
Oct 12 close
$36.06−0.05 (−0.1%)
Gekko Brief
AI summaryOct 12 closeThis week's activity centers on insider selling and an analyst reiteration. CEO Yujiro Hata sold 26,338 shares at an average price of $37.41 for a total of $985,304.58, following an option exercise at $4.31 per share, with a related Form 144 proposing the sale of 230,316 common shares valued at approximately $8.8 million. Separately, Cantor Fitzgerald reiterated an Overweight rating on IDEAYA Biosciences, pointing to upcoming data milestones and noting that the company's Q2 2026 revenue exceeded estimates even as losses continue.
IDYA closed at $36.06, down 0.1%, sitting between its 50-day average of $38.07 and 200-day average of $34.14, with the stock down 4.1% over one month but up 9.9% over six months and 34.6% over the past year. The GekkoIndex reads 65.3, placing the stock in the Accumulation zone, up 4.9 over five points. Gekko Fair Value stands at $43.94, putting the current price 17.9% below that level.
The next earnings date falls on 9 November 2026, 28 days away, within the typical 20-trading-day holding window swing traders might track; the last report on 4 August 2026 showed an EPS of -1.22 against a -1.06 estimate, with a 1.8% reaction, and 3 beats in the last 8 quarters. Seasonality from this point in the calendar has averaged a 7.2% move over the next 20 trading days across 5 years, rising in 4 of them. No insider, Congress, or unusual options activity appears within their respective windows beyond the filings noted.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
IDEAYA Biosciences price vs fair value
Close $36.06200-day averageGekko Fair Value $43.94
IDEAYA Biosciences quick facts
- Market cap
- $3.43B
- P/E ratio
- —
- Forward P/E
- 4.6
- EPS, TTM
- −$1.94
- Revenue, TTM
- $234.1M
- Profit margin
- -74.8%
- Dividend yield
- —
- Beta
- -0.04
- Volume
- 441,476 avg 877,272
- 1-year return
- +34.6%
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±9.1%
- 50-day average
- $38.07
- 200-day average
- $34.14
- Next earnings
- Nov 9
- Shares outstanding
- 96.49M
IDEAYA Biosciences swing-trade checklist
IDEAYA Biosciences scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $36.06 sits between the 50-day ($38.07) and 200-day ($34.14) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.3, Accumulation
Reading 65.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
17.9% below
Price is 17.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.2% on average
From this point in the calendar, the next 20 trading days averaged +7.2% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
IDEAYA Biosciences stock chart and price history
IDEAYA Biosciences closed at $36.06 on Oct 12, 2026, +34.6% over the past year, inside a 52-week range of $26.05 to $42.68.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.1%
- 3 months
- −1.6%
- 6 months
- +9.9%
- 1 year
- +34.6%
The full IDYA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IDYA in Gekko
Follow IDEAYA Biosciences through every session
Put IDYA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IDYA in GekkoFree for 7 days. No credit card required.
About IDEAYA Biosciences
IDEAYA Biosciences works on precision oncology, focusing on medicines matched to patients through molecular testing rather than broad cancer types. It is known for pursuing a drug design strategy called synthetic lethality, which targets cancer cells by exploiting specific genetic vulnerabilities. Its most advanced candidates include a MAT2A-blocking compound being tested in early trials for solid tumors with a particular genetic deletion, and a PKC inhibitor in mid-stage testing for cancers carrying certain gene mutations.
Behind these lead programs, IDEAYA is building out earlier research into other synthetic lethality targets, including inhibitors aimed at tumors with particular DNA repair deficiencies or high genetic instability. Much of this work is carried out alongside outside partners rather than alone. Collaborators named include Cancer Research UK and the University of Manchester on one research program, Pfizer on clinical development and supply for trials spanning melanoma and other solid tumors, and GlaxoSmithKline through a separate alliance.
IDEAYA Biosciences was founded in 2015 and is headquartered in South San Francisco, California. Its shares are listed on the NASDAQ under the ticker IDYA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- ideayabio.com
IDEAYA Biosciences GekkoIndex: the smart money zone
IDEAYA Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.3, in the Accumulation zone, up 4.9 points over five sessions.
65.3Accumulation
Up 4.9 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 28 | +3.0% | +3.3% | ||
| Accumulation (current zone) | 254 | −0.4% | −2.3% | ||
| Neutral | 371 | +0.3% | +1.7% | ||
| Distribution | 26 | −0.4% | −1.3% | ||
| Selling | 3 | Too few readings yet | |||
Average IDYA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the IDYA price, zone by zone.Track IDYA in Gekko
Is IDEAYA Biosciences stock overvalued? Gekko Fair Value
IDEAYA Biosciences trades 17.9% below Gekko Fair Value of $43.94, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what IDEAYA Biosciences shares are worth, recalculated every trading day.
$43.94
Gekko Fair Value, Oct 10, 2026
17.9% Undervalued
At the end of Aug 2026 the price was 14.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IDYA in Gekko
IDEAYA Biosciences insider and Congress trading
No open-market insider purchases were filed for IDEAYA Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IDYA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IDYA, plotted on the chart in Gekko.Open IDYA in Gekko
IDEAYA Biosciences earnings: next date and track record
IDEAYA Biosciences reports on Nov 9, 2026 (28 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 9, 2026
28 days away
- EPS estimate
- −$1.17
- Revenue estimate
- $6.84M
3 of 8reports beat the EPS estimate
±4.5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$1.22 est −$1.06 | $8.86M est $8.02M | +1.8% |
| May 5, 2026 | −$1.11 est −$0.98 | $6.56M est $5.04M | −0.6% |
| Feb 17, 2026 | −$0.94 est −$0.95 | $10.88M est $6.31M | +2.1% |
| Nov 4, 2025 | $1.33 est −$0.95 | $207.8M est $5.95M | −5.4% |
| Aug 5, 2025 | −$0.88 est −$0.85 | — est $2.00M | −5.5% |
| May 6, 2025 | −$0.82 est −$0.75 | — est $2.40M | −12.9% |
| Feb 13, 2025 | −$1.49 est −$0.62 | $7.00M est $2.50M | −4.3% |
| Nov 4, 2024 | −$0.60 est −$0.63 | — est $4.31M | +3.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
IDEAYA Biosciences stock forecast and analyst price targets
Analysts’ average 12-month price target for IDEAYA Biosciences is $52.75, +46.3% from the last close, from 10 firms rating the stock in the last 90 days.
$52.75consensus 12-month target, +46.3% from the last close
Now $36.06Avg $52.75
Low $42High $65
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 27 | LifeSci Capital | $58 | +60.8% |
| Sep 18 | LifeSci Capital | $58 | +60.8% |
| Sep 10 | Citi | $65 | +80.3% |
| Sep 9 | Guggenheim | $57 | +58.1% |
| Sep 9 | LifeSci Capital | $58 | +60.8% |
−2.3%average 20-day move after past Accumulation readings
+7.2%average move over the next 20 trading days in the last 5 years
±4.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
IDEAYA Biosciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, IDEAYA Biosciences averaged +7.2% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.0% | 3 of 5 |
| Next 10 trading days | +1.1% | 4 of 5 |
| Next 15 trading days | +4.3% | 3 of 5 |
| Next 20 trading days | +7.2% | 4 of 5 |
| Next 30 trading days | +8.1% | 3 of 5 |
For scale, IDYA’s typical 20-trading-day move in either direction is about 9.1%.
IDEAYA Biosciences market cap and key statistics
IDEAYA Biosciences’s market cap is $3.43B and revenue of $234.1M over the last twelve months.
Valuation
- Market cap
- $3.43B
- Forward P/E
- 4.6
- EPS, TTM
- −$1.94
- Gekko Fair Value
- $43.94
Trading
- Volume
- 441,476
- Avg volume, 20 days
- 877,272
- 52-week high
- $42.68
- 52-week low
- $26.05
- Shares outstanding
- 96.49M
Financials
- Revenue, TTM
- $234.1M
- Profit margin
- -74.8%
- Return on equity
- -16.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -0.04
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±9.1%
IDEAYA Biosciences stock news this week
Coverage of IDEAYA Biosciences this week reads neutral: 1 positive, 5 neutral and 0 negative headlines.
- Form 144 IDEAYA Biosciences For: 11 October By Investing.comInvesting.com UK, Oct 11
- IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in StockDefense World, Oct 11
- Form 4 Ideaya Biosciences Inc For: 8 October By Investing.comInvesting.com Canada, Oct 9
- Form 4 IDEAYA Biosciences, Inc. For: Oct 06 Filed by: Hata Yujiro SStreetInsider, Oct 8
- Cantor Fitzgerald reiterates Overweight for IDEAYA Biosciences stockAD HOC NEWS, Oct 8
- IDEAYA Biosciences, Inc. (IDYA) Options ChainYahoo! Finance Canada, Oct 8
IDEAYA Biosciences peers
IDEAYA Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
IDEAYA Biosciences stock FAQ
What is IDEAYA Biosciences’s market cap?
IDEAYA Biosciences’s market cap is $3.43B at the Oct 12, 2026 close of $36.06, with 96.49M shares outstanding.
What is the IDEAYA Biosciences stock forecast?
The consensus analyst 12-month price target for IDEAYA Biosciences is $52.75, +46.3% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is IDEAYA Biosciences stock overvalued or undervalued?
On Gekko’s estimate IDEAYA Biosciences is undervalued: the Oct 12, 2026 close of $36.06 is 17.9% below Gekko Fair Value of $43.94. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does IDEAYA Biosciences report earnings next?
IDEAYA Biosciences is expected to report on Nov 9, 2026 (28 days away). Analysts expect earnings of −$1.17 per share on revenue of $6.84M. IDEAYA Biosciences beat the earnings estimate in 3 of its last 8 reports, moving 4.5% on average across the report.
What is IDEAYA Biosciences’s 52-week high and low?
IDEAYA Biosciences’s 52-week high is $42.68 and its 52-week low is $26.05; it closed at $36.06 on Oct 12, 2026, +34.6% over the past year. Over the last five years the shares peaked at $47.74 on Feb 15, 2024.
Is IDEAYA Biosciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See IDEAYA Biosciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.